Health analytics
EU Joint Clinical Assessment
We partner with pharmaceutical companies preparing for EU Joint Clinical Assessment (JCA) to develop strategies and evidence that meet regulatory requirements and clearly demonstrate product value, supporting successful market access across European markets.

The European healthcare landscape is undergoing a significant shift with the introduction of JCA under the new EU HTA regulation
This collaborative, EU-wide approach to evaluating new medicines and medical devices is designed to streamline access across member states. However, navigating the JCA process can be complex - pharmaceutical and MedTech companies must meet unified evidence requirements and tighter timelines while coordinating with multiple stakeholders.
Strategic support for EU Joint Clinical Assessment (JCA)
Across the clinical development-to-access continuum, we advise clients on how best to incorporate JCA requirements - from clinical trial design and evidence generation to submission and beyond.
We tailor our approach to each product and therapeutic area, anticipating potential PICO criteria and adapting to the latest guidance.
How we support our clients
LCP Health Analytics brings extensive experience in health technology assessment, data analysis and strategic consulting
We are committed to being your strategic partner across the development-to-access pathway, supporting you at every step to successfully meet JCA requirements and achieve faster, equitable access for patients.
Explore our range of services
Get in touch
Contact us to learn more about how we can bring you clarity and insight in an increasingly complex life sciences and healthcare environment.













